HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $685,690 | +5.9% | 17,950 | 0.0% | 0.12% | +5.3% |
Q2 2023 | $647,457 | -5.6% | 17,950 | 0.0% | 0.11% | -9.5% |
Q1 2023 | $685,511 | -32.9% | 17,950 | 0.0% | 0.13% | -39.7% |
Q4 2022 | $1,021,355 | +29.3% | 17,950 | 0.0% | 0.21% | +23.7% |
Q2 2022 | $790,000 | +10.3% | 17,950 | 0.0% | 0.17% | +23.4% |
Q1 2022 | $716,000 | -0.8% | 17,950 | 0.0% | 0.14% | +1.5% |
Q4 2021 | $722,000 | -1.1% | 17,950 | 0.0% | 0.14% | -8.2% |
Q3 2021 | $730,000 | -10.4% | 17,950 | 0.0% | 0.15% | -14.5% |
Q2 2021 | $815,000 | +9.0% | 17,950 | 0.0% | 0.17% | +2.4% |
Q1 2021 | $748,000 | -2.5% | 17,950 | 0.0% | 0.17% | -4.5% |
Q4 2020 | $767,000 | +62.5% | 17,950 | 0.0% | 0.18% | +43.1% |
Q3 2020 | $472,000 | -1.9% | 17,950 | 0.0% | 0.12% | -7.5% |
Q2 2020 | $481,000 | +48.9% | 17,950 | 0.0% | 0.13% | +24.3% |
Q1 2020 | $323,000 | +1.6% | 17,950 | 0.0% | 0.11% | +18.9% |
Q4 2019 | $318,000 | +14.4% | 17,950 | 0.0% | 0.09% | +7.1% |
Q3 2019 | $278,000 | -9.7% | 17,950 | 0.0% | 0.08% | -12.5% |
Q2 2019 | $308,000 | – | 17,950 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |